Back to Index
John David Carmichael, MD
Co Director, Pituitary Program At Keck Medical Center
Associate Professor of Clinical Medicine
HCT 1520 San Pablo St Off Campus Los Angeles
+1 323 442 6179


John D. Carmichael, MD, is an associate professor of clinical medicine in the Department of Medicine’s division of endocrinology, diabetes and metabolism at Keck School of Medicine of USC.

Dr. Carmichael is board certified in internal medicine and diabetes, endocrinology and metabolism. His clinical and research interests include the diagnosis and treatment of pituitary disease. He has received NIH funding for his research in growth hormone feedback mechanisms in patients with acromegaly and type 2 diabetes mellitus.

He has written articles for The Journal of? Clinical Endocrinology and Metabolism, Clinical Endocrinology, Pituitary, Endocrine, and Current Opinion in Endocrinology and Diabetes. He sits on the editorial board for Pituitary and is a senior editorial board member for Endocrinology, Diabetes & Metabolism Case Reports. He is a member of the Endocrine Society, the Pituitary Society, and the American Association of Clinical Endocrinologists where he serves on the Pituitary Scientific Committee.

After finishing his clinical training at NYU in 2004, Dr. Carmichael worked as a clinical researcher at NYU focusing on clinical trials in pituitary disease. He received a grant from Genetech to support his work during this time. In 2006, he went on to work at Cedars-Sinai Medical Center in their pituitary center. His work included care of patients with pituitary disease and clinical research in the diagnosis and treatment of patients with pituitary tumors. He held an appointment in the department of medicine at UCLA, devoting his time to the education of medical students, residents and fellows in multiple topics related to pituitary disorders. In 2014, Dr. Carmichael joined the faculty at the Keck School of Medicine of USC.


NIH Loan Repayment Program: Growth Hormone Feedback in Patients with Acromegaly, Type 2 Diabetes Mellitus, and Healthy Adults, 2009-2013

NIH Clinical Research Feasibility Funds (CReFF): Growth Hormone Feedback in Patients with Acromegaly, Type 2 Diabetes Mellitus, and Healthy Adults, 2008-2009


Long-Term Endocrine Outcomes Following Endoscopic Endonasal Transsphenoidal Surgery for Acromegaly and Associated Prognostic Factors. Neurosurgery. 2017 Mar 29. View in: PubMed

The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr Disord. 2017 Mar 09; 17(1):15. View in: PubMed

Follow-up intervals in patients with Cushing's disease: recommendations from a panel of experienced pituitary clinicians. Pituitary. 2017 Mar 09. View in: PubMed

Management of aggressive growth hormone secreting pituitary adenomas. Pituitary. 2016 Dec 16. View in: PubMed

Prolactin-Secreting Pituitary Carcinoma with Dural Metastasis: Diagnosis, Treatment, and Future Directions. World Neurosurg. 2016 Jul; 91:676. e23-8. View in: PubMed

Patterns of pharmacologic treatment in US patients with acromegaly. Curr Med Res Opin. 2016 May; 32(5):799-805. View in: PubMed

Comparative analysis of outcomes following craniotomy and expanded endoscopic endonasal transsphenoidal resection of craniopharyngioma and related tumors: a single-institution study. J Neurosurg. 2016 Mar; 124(3):627-38. View in: PubMed

Gene expression in prolactinomas: a systematic review. Pituitary. 2016 Feb; 19(1):93-104. View in: PubMed


Effects of low dose versus high dose human growth hormone on body composition and lipids in adults with GH deficiency: a meta-analysis of placebo-controlled randomized trials. Pituitary. 2015 Jun; 18(3):297-305. View in: PubMed

Hyperprolactinemia due to spontaneous intracranial hypotension. J Neurosurg. 2015 May; 122(5):1020-5. View in: PubMed

Ectopic ACTH-secreting pituitary adenoma of the sphenoid sinus: case report of endoscopic endonasal resection and systematic review of the literature. Neurosurg Focus. 2015 Feb; 38(2):E10. View in: PubMed

Demographic factors, outcomes, and patient access to transsphenoidal surgery for Cushing's disease: analysis of the Nationwide Inpatient Sample from 2002 to 2010. Neurosurg Focus. 2015 Feb; 38(2):E2. View in: PubMed

Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature. Neurosurg Focus. 2015 Feb; 38(2):E17. View in: PubMed

Cyclic Cushing's disease with misleading inferior petrosal sinus sampling results during a trough phase. Neurosurg Focus. 2015 Feb; 38(2):E7. View in: PubMed

Editorial: Making the diagnosis of cyclic Cushing's syndrome: a position statement from the topic editors. Neurosurg Focus. 2015 Feb; 38(2):E8. View in: PubMed

Introduction: Cushing's disease: a century of evolving diagnostics and therapeutics for an often elusive entity. Neurosurg Focus. 2015 Feb; 38(2):E1. View in: PubMed

A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2015 Jan; 100(1):122-31. View in: PubMed

A protracted and aggressive variant of lymphocytic hypophysitis with mammillary body involvement and cognitive dysfunction. Endocr Pract. 2014 Nov 1; 20(11):e225-9. View in: PubMed

Surgical management of pituicytomas: case series and comprehensive literature review. Pituitary. 2014 Oct; 17(5):399-413. View in: PubMed

Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine. 2014 Jun; 46(2):318-27. View in: PubMed

Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab. 2014 May; 99(5):1825-33. View in: PubMed

Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary. 2013 Sep; 16(3):393-401. View in: PubMed

Mifepristone: is there a place in the treatment of Cushing's disease? Endocrine. Mifepristone: is there a place in the treatment of Cushing's disease? Endocrine. 2013 Aug; 44(1):20-32. View in: PubMed

Too little or too much corticosteroid? Coexisting adrenal insufficiency and Cushing's syndrome from chronic, intermittent use of intranasal betamethasone. Endocrinol Diabetes Metab Case Rep. 2013; 2013:130036. View in: PubMed

Update on the diagnosis and management of hypophysitis. Curr Opin Endocrinol Diabetes Obes. 2012 Aug; 19(4):314-21. View in: PubMed

Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits. Patient Prefer Adherence. 2012; 6:73-82. View in: PubMed

Atypical pituitary adenoma with malignant features. Pituitary. 2011 Mar; 14(1):92-7. View in: PubMed

The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab. 2009 Feb; 94(2):523-7. View in: PubMed

Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab. 2008 Sep; 93(9):3515-8. View in: PubMed

Medical therapy: options and uses. Rev Endocr Metab Disord. 2008 Mar; 9(1):71-81. View in: PubMed

GH peak response to GHRH-arginine: relationship to insulin resistance and other cardiovascular risk factors in a population of adults aged 50-90. Clin Endocrinol (Oxf). 2006 Aug; 65(2):169-77. View in: PubMed

Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab. 2004 May; 89(5):2271-4. View in: PubMed

Powered bySC CTSI